2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 710 | ||
| 355 | ||
| 1 271 | ||
| 9 230 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·27 min sittenNot to be a spoilsport, I have eleven companies in my portfolio, in the feed 36 of the last 40 posts are circio. Great with engagement, but could one perhaps consider rather replying in existing threads so one avoids perceived noise. The stock goes what it goes, precious little the forum can contribute with. So we of course all hope for a tiny little lottery ticket, or to break even. So fear not folks, we are all in the same boat, only that this boat is now overflowing with people shouting land land land.
·46 min sittenWhen is the news coming today
News can come at any time. But well, nothing suggests that this day has particularly high odds. We'll see. Part of the excitement that 😊
·43 min sitten · MuokattuBy the way, I think Solbakken could have credited "his" post to Dweller on TekInvestor. But the points stand regardless! The time when the market is forced to price Circio according to completely different parameters is coming, in my opinion. I actually believe that when we look back a year from now, e.g., on October 29, 2026, many will wonder: Why on earth didn't I buy more at 10.xx kroner? Because already then the company could point to very strong data. And after ESGCT 26 we received further validation of the technology. Among other things, ~200x higher expression with circVec 5.2 at the heart, as much as 95 % cardiac specificity and under 1 % expression in the liver. In addition, we have seen strong data across multiple tissues and indications, as well as therapeutic payload with LAMP2B. These are data that in my view significantly validate the technology. If, for example, an upfront agreement with a Top-5 BP within parts of CNS ticks in, then I think the market will have to find a bigger calculator! On such news alone, I estimate that Circio could easily be priced at 7–10 billion in market cap. Not necessarily because a single agreement in isolation is worth that much, but because circVec will then have received a completely different type of external validation from Big Pharma. Then the market must simultaneously price the probability of more agreements and more programs significantly higher. It is precisely the optionality in the platform that I believe the market is still pricing far too low. In the meantime, one gets to accumulate shares cheaply. When the market actually LOWERS the value of a company after the company presents new, robust and good data, a buying opportunity arises, in my opinion. I am taking advantage of it! I believe history will show that we, ladies and gentlemen, we are pioneers!! 🫶🏼
·59 min sitten · MuokattuWARNING!! AI GENERATED!! Read first, judge afterwards!! Folk, I just have to say it: I get really excited when I look at everything that has happened in Circio this year! 🙌 We follow the share price, get happy when it rises and frustrated when it falls. I feel that way myself too. But stop for a moment and look at what the company has actually achieved. It's starting to become a quite impressive list! ❤️ 200 times higher gene expression in the heart! The new circVec 5.2 design has shown in preclinical studies approximately 200 times higher gene expression in the heart than the conventional AAV9 solution it is compared with. At the same time, 95 percent heart-specific expression and under one percent expression in the liver are reported. I had to read those numbers several times! Further research is needed, but just think about the possibilities if this can contribute to more targeted and effective treatments in humans! 👁️ 🧠 And a lot is happening outside the heart too Previous generations have shown up to around 50 times higher expression in the eye and 60 times in the central nervous system. Circio has also demonstrated an advantage with a therapeutic gene in the heart and long-term expression with T-cell targeted lipid nanoparticles. It's this breadth that I like so much. Several applications are being investigated, and researchers are getting more and more to build on! 🤝 A pharma giant is funding the research The study with one of the world's five largest pharmaceutical companies moved in April from successful laboratory tests to testing in living organisms. The partner is funding the entire study! A larger licensing agreement must still be secured, but the project has passed an important milestone. I think we have good reason to be pleased about that! 🌍 Look at the collaborations that have materialized! 🧬 Acuitas: Testing circVec with T-cell targeted lipid nanoparticles for possible future in vivo CAR-T therapy. ❤️ AaviGen: Collaborating on more targeted gene therapy against heart disease. 💪 GenAssist: Exploring solutions for muscle diseases and cell therapy. 🛡️ Tcelltech: Testing combinations for more durable expression in CAR-T and TCR-T cells. 🔬 Avenue Biosciences: Investigating increased production and secretion of therapeutic proteins. 🔄 Full Circles Therapeutics: Exploring solutions aiming for lower immune reactions and the possibility of repeated dosing. 📦 TraffikGene: Testing new ways to deliver circVec to cells and tissues. At the half-year report, Circio reported over 20 active research collaborations! These are research and evaluation agreements, and several commercial agreements must still follow. But so many possibilities under testing I find enormously encouraging! 💰 Around 820 million kroner raised in 2026! Approximately 620 million in the first half and an additional around 200 million from new international investors in September. The company states funding through 2030, while ambitions and activity are being increased. The September capital will mainly accelerate the in vivo CAR-T initiative. Yes, the share issues have caused dilution. They have also given researchers the resources to pursue the opportunities they see. Now there is financial muscle behind the ambitions! 👩🔬 Heavy experience into the board Dinah Sah has been elected with over 30 years of research experience, including from Voyager and Alnylam. She has experience in taking RNA and gene therapy programs from early research into clinical trials. Robert Burns has also been elected back, with his long familiarity with Circio. It is good to see that competence is being strengthened in step with the ambitions! 📜 The technology is being developed and patented In May, Circio filed a new patent application for a genetic element that increases efficiency in the formation of circular RNA by approximately four times compared to constructs without the element. Yet another concrete result from the further development of the platform! 🎤 International attention Circio has been selected for oral presentations at both ASGCT and ESGCT this year. At ESGCT they are participating with one oral presentation and two posters. The researchers get to showcase the results in front of professionals and potential international collaborators! 📅 More to follow going forward! 🔹 Toward the end of November, a research update is planned with ESGCT data and results from ongoing studies in the heart and eye. 🔹 The first quarter of 2027 has seen announcements of the start of studies in animal models for heart disease. 🙌 It's the sum that makes me so optimistic! Treatment effect and safety must be further documented, and the research must eventually yield commercial agreements. But goodness me, so much has fallen into place! ✅ Stronger research results ✅ More collaborations and opportunities ✅ Capital for further development ✅ More experience on the board ✅ Exciting milestones ahead of us I believe in the potential in Circio. After everything that has happened this year, I have gotten even more concrete reasons to look forward to the continuation. This will be exciting to follow further together with you! 🙌🧬🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27 min sittenNot to be a spoilsport, I have eleven companies in my portfolio, in the feed 36 of the last 40 posts are circio. Great with engagement, but could one perhaps consider rather replying in existing threads so one avoids perceived noise. The stock goes what it goes, precious little the forum can contribute with. So we of course all hope for a tiny little lottery ticket, or to break even. So fear not folks, we are all in the same boat, only that this boat is now overflowing with people shouting land land land.
- ·46 min sittenWhen is the news coming todayNews can come at any time. But well, nothing suggests that this day has particularly high odds. We'll see. Part of the excitement that 😊
- ·43 min sitten · MuokattuBy the way, I think Solbakken could have credited "his" post to Dweller on TekInvestor. But the points stand regardless! The time when the market is forced to price Circio according to completely different parameters is coming, in my opinion. I actually believe that when we look back a year from now, e.g., on October 29, 2026, many will wonder: Why on earth didn't I buy more at 10.xx kroner? Because already then the company could point to very strong data. And after ESGCT 26 we received further validation of the technology. Among other things, ~200x higher expression with circVec 5.2 at the heart, as much as 95 % cardiac specificity and under 1 % expression in the liver. In addition, we have seen strong data across multiple tissues and indications, as well as therapeutic payload with LAMP2B. These are data that in my view significantly validate the technology. If, for example, an upfront agreement with a Top-5 BP within parts of CNS ticks in, then I think the market will have to find a bigger calculator! On such news alone, I estimate that Circio could easily be priced at 7–10 billion in market cap. Not necessarily because a single agreement in isolation is worth that much, but because circVec will then have received a completely different type of external validation from Big Pharma. Then the market must simultaneously price the probability of more agreements and more programs significantly higher. It is precisely the optionality in the platform that I believe the market is still pricing far too low. In the meantime, one gets to accumulate shares cheaply. When the market actually LOWERS the value of a company after the company presents new, robust and good data, a buying opportunity arises, in my opinion. I am taking advantage of it! I believe history will show that we, ladies and gentlemen, we are pioneers!! 🫶🏼
- ·59 min sitten · MuokattuWARNING!! AI GENERATED!! Read first, judge afterwards!! Folk, I just have to say it: I get really excited when I look at everything that has happened in Circio this year! 🙌 We follow the share price, get happy when it rises and frustrated when it falls. I feel that way myself too. But stop for a moment and look at what the company has actually achieved. It's starting to become a quite impressive list! ❤️ 200 times higher gene expression in the heart! The new circVec 5.2 design has shown in preclinical studies approximately 200 times higher gene expression in the heart than the conventional AAV9 solution it is compared with. At the same time, 95 percent heart-specific expression and under one percent expression in the liver are reported. I had to read those numbers several times! Further research is needed, but just think about the possibilities if this can contribute to more targeted and effective treatments in humans! 👁️ 🧠 And a lot is happening outside the heart too Previous generations have shown up to around 50 times higher expression in the eye and 60 times in the central nervous system. Circio has also demonstrated an advantage with a therapeutic gene in the heart and long-term expression with T-cell targeted lipid nanoparticles. It's this breadth that I like so much. Several applications are being investigated, and researchers are getting more and more to build on! 🤝 A pharma giant is funding the research The study with one of the world's five largest pharmaceutical companies moved in April from successful laboratory tests to testing in living organisms. The partner is funding the entire study! A larger licensing agreement must still be secured, but the project has passed an important milestone. I think we have good reason to be pleased about that! 🌍 Look at the collaborations that have materialized! 🧬 Acuitas: Testing circVec with T-cell targeted lipid nanoparticles for possible future in vivo CAR-T therapy. ❤️ AaviGen: Collaborating on more targeted gene therapy against heart disease. 💪 GenAssist: Exploring solutions for muscle diseases and cell therapy. 🛡️ Tcelltech: Testing combinations for more durable expression in CAR-T and TCR-T cells. 🔬 Avenue Biosciences: Investigating increased production and secretion of therapeutic proteins. 🔄 Full Circles Therapeutics: Exploring solutions aiming for lower immune reactions and the possibility of repeated dosing. 📦 TraffikGene: Testing new ways to deliver circVec to cells and tissues. At the half-year report, Circio reported over 20 active research collaborations! These are research and evaluation agreements, and several commercial agreements must still follow. But so many possibilities under testing I find enormously encouraging! 💰 Around 820 million kroner raised in 2026! Approximately 620 million in the first half and an additional around 200 million from new international investors in September. The company states funding through 2030, while ambitions and activity are being increased. The September capital will mainly accelerate the in vivo CAR-T initiative. Yes, the share issues have caused dilution. They have also given researchers the resources to pursue the opportunities they see. Now there is financial muscle behind the ambitions! 👩🔬 Heavy experience into the board Dinah Sah has been elected with over 30 years of research experience, including from Voyager and Alnylam. She has experience in taking RNA and gene therapy programs from early research into clinical trials. Robert Burns has also been elected back, with his long familiarity with Circio. It is good to see that competence is being strengthened in step with the ambitions! 📜 The technology is being developed and patented In May, Circio filed a new patent application for a genetic element that increases efficiency in the formation of circular RNA by approximately four times compared to constructs without the element. Yet another concrete result from the further development of the platform! 🎤 International attention Circio has been selected for oral presentations at both ASGCT and ESGCT this year. At ESGCT they are participating with one oral presentation and two posters. The researchers get to showcase the results in front of professionals and potential international collaborators! 📅 More to follow going forward! 🔹 Toward the end of November, a research update is planned with ESGCT data and results from ongoing studies in the heart and eye. 🔹 The first quarter of 2027 has seen announcements of the start of studies in animal models for heart disease. 🙌 It's the sum that makes me so optimistic! Treatment effect and safety must be further documented, and the research must eventually yield commercial agreements. But goodness me, so much has fallen into place! ✅ Stronger research results ✅ More collaborations and opportunities ✅ Capital for further development ✅ More experience on the board ✅ Exciting milestones ahead of us I believe in the potential in Circio. After everything that has happened this year, I have gotten even more concrete reasons to look forward to the continuation. This will be exciting to follow further together with you! 🙌🧬🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 710 | ||
| 355 | ||
| 1 271 | ||
| 9 230 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27 min sittenNot to be a spoilsport, I have eleven companies in my portfolio, in the feed 36 of the last 40 posts are circio. Great with engagement, but could one perhaps consider rather replying in existing threads so one avoids perceived noise. The stock goes what it goes, precious little the forum can contribute with. So we of course all hope for a tiny little lottery ticket, or to break even. So fear not folks, we are all in the same boat, only that this boat is now overflowing with people shouting land land land.
- ·46 min sittenWhen is the news coming todayNews can come at any time. But well, nothing suggests that this day has particularly high odds. We'll see. Part of the excitement that 😊
- ·43 min sitten · MuokattuBy the way, I think Solbakken could have credited "his" post to Dweller on TekInvestor. But the points stand regardless! The time when the market is forced to price Circio according to completely different parameters is coming, in my opinion. I actually believe that when we look back a year from now, e.g., on October 29, 2026, many will wonder: Why on earth didn't I buy more at 10.xx kroner? Because already then the company could point to very strong data. And after ESGCT 26 we received further validation of the technology. Among other things, ~200x higher expression with circVec 5.2 at the heart, as much as 95 % cardiac specificity and under 1 % expression in the liver. In addition, we have seen strong data across multiple tissues and indications, as well as therapeutic payload with LAMP2B. These are data that in my view significantly validate the technology. If, for example, an upfront agreement with a Top-5 BP within parts of CNS ticks in, then I think the market will have to find a bigger calculator! On such news alone, I estimate that Circio could easily be priced at 7–10 billion in market cap. Not necessarily because a single agreement in isolation is worth that much, but because circVec will then have received a completely different type of external validation from Big Pharma. Then the market must simultaneously price the probability of more agreements and more programs significantly higher. It is precisely the optionality in the platform that I believe the market is still pricing far too low. In the meantime, one gets to accumulate shares cheaply. When the market actually LOWERS the value of a company after the company presents new, robust and good data, a buying opportunity arises, in my opinion. I am taking advantage of it! I believe history will show that we, ladies and gentlemen, we are pioneers!! 🫶🏼
- ·59 min sitten · MuokattuWARNING!! AI GENERATED!! Read first, judge afterwards!! Folk, I just have to say it: I get really excited when I look at everything that has happened in Circio this year! 🙌 We follow the share price, get happy when it rises and frustrated when it falls. I feel that way myself too. But stop for a moment and look at what the company has actually achieved. It's starting to become a quite impressive list! ❤️ 200 times higher gene expression in the heart! The new circVec 5.2 design has shown in preclinical studies approximately 200 times higher gene expression in the heart than the conventional AAV9 solution it is compared with. At the same time, 95 percent heart-specific expression and under one percent expression in the liver are reported. I had to read those numbers several times! Further research is needed, but just think about the possibilities if this can contribute to more targeted and effective treatments in humans! 👁️ 🧠 And a lot is happening outside the heart too Previous generations have shown up to around 50 times higher expression in the eye and 60 times in the central nervous system. Circio has also demonstrated an advantage with a therapeutic gene in the heart and long-term expression with T-cell targeted lipid nanoparticles. It's this breadth that I like so much. Several applications are being investigated, and researchers are getting more and more to build on! 🤝 A pharma giant is funding the research The study with one of the world's five largest pharmaceutical companies moved in April from successful laboratory tests to testing in living organisms. The partner is funding the entire study! A larger licensing agreement must still be secured, but the project has passed an important milestone. I think we have good reason to be pleased about that! 🌍 Look at the collaborations that have materialized! 🧬 Acuitas: Testing circVec with T-cell targeted lipid nanoparticles for possible future in vivo CAR-T therapy. ❤️ AaviGen: Collaborating on more targeted gene therapy against heart disease. 💪 GenAssist: Exploring solutions for muscle diseases and cell therapy. 🛡️ Tcelltech: Testing combinations for more durable expression in CAR-T and TCR-T cells. 🔬 Avenue Biosciences: Investigating increased production and secretion of therapeutic proteins. 🔄 Full Circles Therapeutics: Exploring solutions aiming for lower immune reactions and the possibility of repeated dosing. 📦 TraffikGene: Testing new ways to deliver circVec to cells and tissues. At the half-year report, Circio reported over 20 active research collaborations! These are research and evaluation agreements, and several commercial agreements must still follow. But so many possibilities under testing I find enormously encouraging! 💰 Around 820 million kroner raised in 2026! Approximately 620 million in the first half and an additional around 200 million from new international investors in September. The company states funding through 2030, while ambitions and activity are being increased. The September capital will mainly accelerate the in vivo CAR-T initiative. Yes, the share issues have caused dilution. They have also given researchers the resources to pursue the opportunities they see. Now there is financial muscle behind the ambitions! 👩🔬 Heavy experience into the board Dinah Sah has been elected with over 30 years of research experience, including from Voyager and Alnylam. She has experience in taking RNA and gene therapy programs from early research into clinical trials. Robert Burns has also been elected back, with his long familiarity with Circio. It is good to see that competence is being strengthened in step with the ambitions! 📜 The technology is being developed and patented In May, Circio filed a new patent application for a genetic element that increases efficiency in the formation of circular RNA by approximately four times compared to constructs without the element. Yet another concrete result from the further development of the platform! 🎤 International attention Circio has been selected for oral presentations at both ASGCT and ESGCT this year. At ESGCT they are participating with one oral presentation and two posters. The researchers get to showcase the results in front of professionals and potential international collaborators! 📅 More to follow going forward! 🔹 Toward the end of November, a research update is planned with ESGCT data and results from ongoing studies in the heart and eye. 🔹 The first quarter of 2027 has seen announcements of the start of studies in animal models for heart disease. 🙌 It's the sum that makes me so optimistic! Treatment effect and safety must be further documented, and the research must eventually yield commercial agreements. But goodness me, so much has fallen into place! ✅ Stronger research results ✅ More collaborations and opportunities ✅ Capital for further development ✅ More experience on the board ✅ Exciting milestones ahead of us I believe in the potential in Circio. After everything that has happened this year, I have gotten even more concrete reasons to look forward to the continuation. This will be exciting to follow further together with you! 🙌🧬🚀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 710 | ||
| 355 | ||
| 1 271 | ||
| 9 230 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt